OSR (NASDAQ:OSRH) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of OSR (NASDAQ:OSRH) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

OSR Price Performance

Shares of OSR stock opened at $0.69 on Friday. The business has a 50-day moving average of $0.49 and a 200-day moving average of $0.58. The company has a market capitalization of $22.96 million, a PE ratio of -0.54 and a beta of 0.59. OSR has a 1-year low of $0.38 and a 1-year high of $1.79.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 55.30% of the company’s stock.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.